Global Regulatory</a>&nbsp;compliance environment means the impact of these requirements continues to expand, placing an increasing burden on drug and medical device manufacturers. A recent global survey of pharmaceutical CEOs<sup>1</sup> shows an increase in regulatory scrutiny across many aspects of the business, including sales and marketing practices, government drug price reporting, data privacy management, and clinical operations. Changes in industry regulations are now viewed as one of the top three disruptive business trends faced by pharmaceutical and life sciences organizations, and many pharma leaders view these changes as a threat to their growth.<sup>2</sup></p> <p>But they don&rsquo;t have to be.&nbsp;</p> <p>Compliance has long been viewed as a cost-center and a necessity, but leading organizations are recognizing opportunities for innovation in this space.&nbsp;</p> <p>Meeting regulatory compliance requirements as efficiently as possible means creating a culture of proactivity to ensure products meet the needs of patients and that the company operates ethically, which translates into company growth, reduced risk, and a stronger brand image in the eyes of the public. Conversely, when companies treat compliance as a must-do rather than a value-add and fail to invest in these processes, they increase risks that could involve compromised patient safety, delays or denials of product approvals, license withdrawals, financial penalties, and in the worst case, criminal penalties. These adverse circumstances can be devastating to the individual life sciences company and generate negative public perception that affects the entire industry.&nbsp;</p> <p>To avoid these risks and add value to the compliance process, companies need to look for synergies in their regulatory compliance activities that be used to build a business case for technology and talent investment, and to identify opportunities to remove waste and redundancy across the full product life cycle.</p> <p><img alt="" class="img-responsive" src=https://www.iqvia.com/blogs/2018/10/"-/media/fe1b55f69f2c48f598d74f1d610630e6.ashx?h=68%25&amp;w=100%25%22 style="width: 100%; height: 68%;" /></p> <h4>Tearing down obstacles</h4> <p>When companies take a holistic view of the impact of regulations on quality, regulatory, safety, and commercial compliance requirements, they can identify common challenges that restrict overall productivity, and generate hidden waste and risk. This is the first step in driving innovation in the regulatory and compliance environment.</p> <p>These obstacles typically include:</p> <ul> <li><strong>Lack of innovative technology and harmonization: </strong>While the pharma industry has invested billions in advanced technology, those investments have been slow to trickle down to compliance. Aging and disconnected platforms and lack of automation add time, cost, and poor visibility to the compliance process.</li> <li><strong>Difficulty staying abreast of shifting global and local regulations: </strong>Global pharmaceutical and medical device companies &ndash; and smaller biotech companies with global aspirations &ndash; need experts with a keen understanding of global regulations and how they affect the development process. Staying abreast of regulatory changes, by country and region, can be a tremendous resource drain but it vital to achieving and maintaining compliance. </li> <li><strong>Multiple silos/vendors/manual processes:</strong> Many companies lack horizontal integration of compliance tasks. Numerous vendors, disparate platforms, and lack of automation result in duplicative spending, lack of internal cost transparency, and inefficient operations. </li> <li><strong>High volumes of unstructured data.</strong> The lack of conformity across data sets complicates downstream reporting and can delay the real-time insights required to maintain compliance.</li> </ul> <p>Once these obstacles are identified, business leaders can make the case for upgrades and investments. These may include implementation of centralized technology systems with advanced analytics capabilities to manage compliance tasks and capture data in a single data repository; hiring new talent or collaborating with industry partners to ensure all development decisions align with the latest global regulatory trends; and harmonizing delivery of external compliance tasks under a single industry partner who can provide deep domain expertise to increase transparency, avoid overlap, and leverage best practices to more efficiently meet all of the organization&rsquo;s compliance needs.</p> <h4>Taking on the Future</h4> <p>Transforming a company&rsquo;s approach to compliance takes time and resources. Some may start with pilot projects to update a single piece of technology or to automate one aspect of their reporting, while others will invest in end-to-end solutions that radically change the culture of compliance in their organizations. Regardless of the approach, these companies should do their research, and work with partners who can help them identify near-term projects that will drive early measurable savings and lay the groundwork for larger transformation efforts. </p> <p>Although these transformations take time, they can significantly lower total costs while enhancing regulatory compliance and, in turn, reducing risks for patients, product development, and company reputation.</p> <p>&nbsp;---------------------------------------</p> <p style="font-size:12px;"><sup>1</sup> <a rel="noopener noreferrer" rel="noopener noreferrer" href=https://www.iqvia.com/blogs/2018/10/"https://www.pwc.com/il/en/pharmaceuticals/managing-regulatory-compliance.html" target="_blank">https://www.pwc.com/il/en/pharmaceuticals/managing-regulatory-compliance.html</a></p> <p style="font-size:12px;"><sup>2</sup><a rel="noopener noreferrer" rel="noopener noreferrer" href=https://www.iqvia.com/blogs/2018/10/"https://www.pwc.com/il/en/pharmaceuticals/managing-regulatory-compliance.html" target="_blank">https://www.pwc.com/gx/en/ceo-survey/industry/pdfs/pwc-ceo-survey-pharma-life-sciences.pdf</a></p>" /> Global Regulatory</a>&nbsp;compliance environment means the impact of these requirements continues to expand, placing an increasing burden on drug and medical device manufacturers. A recent global survey of pharmaceutical CEOs<sup>1</sup> shows an increase in regulatory scrutiny across many aspects of the business, including sales and marketing practices, government drug price reporting, data privacy management, and clinical operations. Changes in industry regulations are now viewed as one of the top three disruptive business trends faced by pharmaceutical and life sciences organizations, and many pharma leaders view these changes as a threat to their growth.<sup>2</sup></p> <p>But they don&rsquo;t have to be.&nbsp;</p> <p>Compliance has long been viewed as a cost-center and a necessity, but leading organizations are recognizing opportunities for innovation in this space.&nbsp;</p> <p>Meeting regulatory compliance requirements as efficiently as possible means creating a culture of proactivity to ensure products meet the needs of patients and that the company operates ethically, which translates into company growth, reduced risk, and a stronger brand image in the eyes of the public. Conversely, when companies treat compliance as a must-do rather than a value-add and fail to invest in these processes, they increase risks that could involve compromised patient safety, delays or denials of product approvals, license withdrawals, financial penalties, and in the worst case, criminal penalties. These adverse circumstances can be devastating to the individual life sciences company and generate negative public perception that affects the entire industry.&nbsp;</p> <p>To avoid these risks and add value to the compliance process, companies need to look for synergies in their regulatory compliance activities that be used to build a business case for technology and talent investment, and to identify opportunities to remove waste and redundancy across the full product life cycle.</p> <p><img alt="" class="img-responsive" src=https://www.iqvia.com/blogs/2018/10/"-/media/fe1b55f69f2c48f598d74f1d610630e6.ashx?h=68%25&amp;w=100%25%22 style="width: 100%; height: 68%;" /></p> <h4>Tearing down obstacles</h4> <p>When companies take a holistic view of the impact of regulations on quality, regulatory, safety, and commercial compliance requirements, they can identify common challenges that restrict overall productivity, and generate hidden waste and risk. This is the first step in driving innovation in the regulatory and compliance environment.</p> <p>These obstacles typically include:</p> <ul> <li><strong>Lack of innovative technology and harmonization: </strong>While the pharma industry has invested billions in advanced technology, those investments have been slow to trickle down to compliance. Aging and disconnected platforms and lack of automation add time, cost, and poor visibility to the compliance process.</li> <li><strong>Difficulty staying abreast of shifting global and local regulations: </strong>Global pharmaceutical and medical device companies &ndash; and smaller biotech companies with global aspirations &ndash; need experts with a keen understanding of global regulations and how they affect the development process. Staying abreast of regulatory changes, by country and region, can be a tremendous resource drain but it vital to achieving and maintaining compliance. </li> <li><strong>Multiple silos/vendors/manual processes:</strong> Many companies lack horizontal integration of compliance tasks. Numerous vendors, disparate platforms, and lack of automation result in duplicative spending, lack of internal cost transparency, and inefficient operations. </li> <li><strong>High volumes of unstructured data.</strong> The lack of conformity across data sets complicates downstream reporting and can delay the real-time insights required to maintain compliance.</li> </ul> <p>Once these obstacles are identified, business leaders can make the case for upgrades and investments. These may include implementation of centralized technology systems with advanced analytics capabilities to manage compliance tasks and capture data in a single data repository; hiring new talent or collaborating with industry partners to ensure all development decisions align with the latest global regulatory trends; and harmonizing delivery of external compliance tasks under a single industry partner who can provide deep domain expertise to increase transparency, avoid overlap, and leverage best practices to more efficiently meet all of the organization&rsquo;s compliance needs.</p> <h4>Taking on the Future</h4> <p>Transforming a company&rsquo;s approach to compliance takes time and resources. Some may start with pilot projects to update a single piece of technology or to automate one aspect of their reporting, while others will invest in end-to-end solutions that radically change the culture of compliance in their organizations. Regardless of the approach, these companies should do their research, and work with partners who can help them identify near-term projects that will drive early measurable savings and lay the groundwork for larger transformation efforts. </p> <p>Although these transformations take time, they can significantly lower total costs while enhancing regulatory compliance and, in turn, reducing risks for patients, product development, and company reputation.</p> <p>&nbsp;---------------------------------------</p> <p style="font-size:12px;"><sup>1</sup> <a rel="noopener noreferrer" rel="noopener noreferrer" href=https://www.iqvia.com/blogs/2018/10/"https://www.pwc.com/il/en/pharmaceuticals/managing-regulatory-compliance.html" target="_blank">https://www.pwc.com/il/en/pharmaceuticals/managing-regulatory-compliance.html</a></p> <p style="font-size:12px;"><sup>2</sup><a rel="noopener noreferrer" rel="noopener noreferrer" href=https://www.iqvia.com/blogs/2018/10/"https://www.pwc.com/il/en/pharmaceuticals/managing-regulatory-compliance.html" target="_blank">https://www.pwc.com/gx/en/ceo-survey/industry/pdfs/pwc-ceo-survey-pharma-life-sciences.pdf</a></p>" />
Regions
MAIN/REGIONS
regions/
Regions
  1. Americas
  2. Asia & Oceania
  3. Europe
  4. Middle East & Africa
  1. Solutions
  2. Products
  3. Insights
  4. About
  5. Careers
  6. Contact Us
MAIN/search
MAIN/Solutions
Solutions/
SOLUTIONS
  • Research & Development
  • Real World Evidence
  • Commercialization
  • Integrated Global Compliance
  • Technologies
LIFE SCIENCE SEGMENTS
HEALTHCARE SEGMENTS
THERAPEUTIC AREAS

IQVIA TECHNOLOGIES

"Harness technology for a healthier world.

EXPLORE MORE
Harness the power to transform clinical development

Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.

Research & Development Overview
Research & Development Quick Links
Real World Evidence. Real Confidence. Real Results.

Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.

REAL WORLD EVIDENCE OVERVIEW
Real World Evidence Quick Links
See markets more clearly. Opportunities more often.

Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.

COMMERCIALIZATION OVERVIEW
Commercialization Quick Links
Service driven. Tech-enabled. Integrated compliance.

Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety and quality.

COMPLIANCE OVERVIEW
Integrated Global Compliance Quick Links
Intelligence that transforms life sciences end-to-end.

When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.

TECHNOLOGIES OVERVIEW
Technology Quick Links
MAIN/Products
Products/
CLINICAL PRODUCTS
COMMERCIAL PRODUCTS
COMPLIANCE, SAFETY, REG PRODUCTS
REAL WORLD PRODUCTS

CASE STUDY

"Data in a Day

LEARN MORE
MAIN/Insights
Insights/
BLOGS, WHITE PAPERS & CASE STUDIES

Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.

DISCOVER INSIGHTS
THE IQVIA INSTITUTE

An in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.

SEE LATEST REPORTS

INSTITUTE REPORT

"Global Trends in R&D 2023

READ MORE

Webinar

"Global Consumer Health Trends 2023 Webinar Series

Learn more

WHITE PAPER

"DCTs Deliver Big ROI

LEARN MORE

WHITE PAPER

"Capturing value at scale: The $4 billion RWE imperative

LEARN MORE
MAIN/About
About/
FEATURED INNOVATIONS
  • Connected Intelligence
  • AI & Machine Learning
  • Human Data Science Cloud
  • IQVIA Innovation Hub
  • Decentralized Trials
  • Genomics
WHO WE ARE
NEWS & RESOURCES

INVESTOR RELATIONS

"Visit our investor relations site for more information.

LEARN MORE
Unlock your potential to drive healthcare forward

By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.

LEARN MORE
AI & Machine Learning with a healthcare IQ.

Artificial intelligence is accelerating opportunities. Realizing the benefits for healthcare requires the right expertise. Together, we can solve the problems of today, and drive the breakthroughs of tomorrow.

LEARN MORE
Your healthcare data deserves more than just a cloud.

The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.

LEARN MORE
Innovations make an impact when bold ideas meet powerful partnerships

The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.

LEARN MORE
Proven, faster DCT solutions

IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.

LEARN MORE
Unlock the power of genomic research.

IQVIA enables genomic research via global access to a network of genomic-clinical data, proprietary technologies that enable federated analytics, and therapeutic area & bioinformatics expertise to help you answer your most pressing research questions.

LEARN MORE
MAIN/Careers
Careers/
WORKING AT IQVIA

Our mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.

LEARN MORE
LIFE AT IQVIA

Careers, culture and everything in between. Find out what’s going on right here, right now.

LEARN MORE

WE’RE HIRING

"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.

SEARCH JOBS
MAIN/Contact Us
Contact Us/
Blog
Transform Your Approach to Compliance
Bill Buzzeo, General Manager, U.S. Center of Compliance Excellence, IQVIA
Oct 12, 2018
  • Blogs
  • Transform Your Approach to Compliance

From concept to market

Quality, regulatory, safety, and commercial compliance are the building blocks that ensure medicines and devices are safe and effective and that companies operate in an ethical manner. However, the shifting Global Regulatory compliance environment means the impact of these requirements continues to expand, placing an increasing burden on drug and medical device manufacturers. A recent global survey of pharmaceutical CEOs1 shows an increase in regulatory scrutiny across many aspects of the business, including sales and marketing practices, government drug price reporting, data privacy management, and clinical operations. Changes in industry regulations are now viewed as one of the top three disruptive business trends faced by pharmaceutical and life sciences organizations, and many pharma leaders view these changes as a threat to their growth.2

But they don’t have to be. 

Compliance has long been viewed as a cost-center and a necessity, but leading organizations are recognizing opportunities for innovation in this space. 

Meeting regulatory compliance requirements as efficiently as possible means creating a culture of proactivity to ensure products meet the needs of patients and that the company operates ethically, which translates into company growth, reduced risk, and a stronger brand image in the eyes of the public. Conversely, when companies treat compliance as a must-do rather than a value-add and fail to invest in these processes, they increase risks that could involve compromised patient safety, delays or denials of product approvals, license withdrawals, financial penalties, and in the worst case, criminal penalties. These adverse circumstances can be devastating to the individual life sciences company and generate negative public perception that affects the entire industry. 

To avoid these risks and add value to the compliance process, companies need to look for synergies in their regulatory compliance activities that be used to build a business case for technology and talent investment, and to identify opportunities to remove waste and redundancy across the full product life cycle.

Tearing down obstacles

When companies take a holistic view of the impact of regulations on quality, regulatory, safety, and commercial compliance requirements, they can identify common challenges that restrict overall productivity, and generate hidden waste and risk. This is the first step in driving innovation in the regulatory and compliance environment.

These obstacles typically include:

  • Lack of innovative technology and harmonization: While the pharma industry has invested billions in advanced technology, those investments have been slow to trickle down to compliance. Aging and disconnected platforms and lack of automation add time, cost, and poor visibility to the compliance process.
  • Difficulty staying abreast of shifting global and local regulations: Global pharmaceutical and medical device companies – and smaller biotech companies with global aspirations – need experts with a keen understanding of global regulations and how they affect the development process. Staying abreast of regulatory changes, by country and region, can be a tremendous resource drain but it vital to achieving and maintaining compliance.
  • Multiple silos/vendors/manual processes: Many companies lack horizontal integration of compliance tasks. Numerous vendors, disparate platforms, and lack of automation result in duplicative spending, lack of internal cost transparency, and inefficient operations.
  • High volumes of unstructured data. The lack of conformity across data sets complicates downstream reporting and can delay the real-time insights required to maintain compliance.

Once these obstacles are identified, business leaders can make the case for upgrades and investments. These may include implementation of centralized technology systems with advanced analytics capabilities to manage compliance tasks and capture data in a single data repository; hiring new talent or collaborating with industry partners to ensure all development decisions align with the latest global regulatory trends; and harmonizing delivery of external compliance tasks under a single industry partner who can provide deep domain expertise to increase transparency, avoid overlap, and leverage best practices to more efficiently meet all of the organization’s compliance needs.

Taking on the Future

Transforming a company’s approach to compliance takes time and resources. Some may start with pilot projects to update a single piece of technology or to automate one aspect of their reporting, while others will invest in end-to-end solutions that radically change the culture of compliance in their organizations. Regardless of the approach, these companies should do their research, and work with partners who can help them identify near-term projects that will drive early measurable savings and lay the groundwork for larger transformation efforts.

Although these transformations take time, they can significantly lower total costs while enhancing regulatory compliance and, in turn, reducing risks for patients, product development, and company reputation.

 ---------------------------------------

1 https://www.pwc.com/il/en/pharmaceuticals/managing-regulatory-compliance.html

2https://www.pwc.com/gx/en/ceo-survey/industry/pdfs/pwc-ceo-survey-pharma-life-sciences.pdf

Men reviewing information on computer

Take a Proactive Approach to Regulatory Compliance

Learn more

Related solutions

Integrated Global Compliance

Meet the challenge of changing stakeholder demands and increasing cost constraints with IQVIA's integrated technology services and analytics-driven offerings.

Contact Us